Superluminal Medicines is a Boston-based biotechnology company that integrates AI/ML, protein dynamics and structural biology to discover small-molecule drugs against hard-to-drug G protein-coupled receptor (GPCR) targets, pairing Agentic Cryo-EM structure generation with machine-learning design and predictive ADME/toxicology models. Its wholly owned lead program is a selective, biased MC4R agonist for rare genetic forms of obesity and hypothalamic obesity, expected to enter Phase 1 trials by the end of 2026. The company also advances pharma collaborations, including a partnership with Eli Lilly and Company on small-molecule GPCR programs for cardiometabolic diseases and obesity.
1
Round
1
Industry
5
Tags
Sep 3, 2026
Latest raise
Funding activity · 1 round
Sep 3, 2026
$60M
Series B
Led by BVF Partners
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
